Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 1.69779286927 | 0.589 | 0.9374 | 0.5475 | 625930 | 0.70082037 | CS |
4 | -0.032 | -5.07131537242 | 0.631 | 1.09 | 0.5209 | 361336 | 0.73696922 | CS |
12 | -0.171 | -22.2077922078 | 0.77 | 1.1099 | 0.49 | 380835 | 0.81588585 | CS |
26 | -1.031 | -63.2515337423 | 1.63 | 1.64 | 0.49 | 183497 | 0.81636391 | CS |
52 | -0.201 | -25.125 | 0.8 | 1.87 | 0.49 | 99140 | 0.84729365 | CS |
156 | -6.641 | -91.726519337 | 7.24 | 7.6 | 0.49 | 59715 | 2.24612089 | CS |
260 | -14.361 | -95.9959893048 | 14.96 | 19.56 | 0.49 | 344281 | 10.57384395 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.